These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34216282)

  • 21. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
    Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    Crawford ED; Hafron JM; Debruyne F; Wallis C; Chang S; Garnick MB
    J Urol; 2024 Jan; 211(1):63-70. PubMed ID: 37796473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen deprivation therapy and side effects: are GnRH antagonists safer?
    Freedland SJ; Abrahamsson PA
    Asian J Androl; 2021; 23(1):3-10. PubMed ID: 32655041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk with androgen deprivation therapy.
    Rosenberg MT
    Int J Clin Pract; 2020 Mar; 74(3):e13449. PubMed ID: 31755635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.
    Kim J; Freeman K; Ayala A; Mullen M; Sun Z; Rhee JW
    Curr Oncol Rep; 2023 Sep; 25(9):965-977. PubMed ID: 37273124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of Cardiovascular Events in Patients With Prostate Cancer and Treated With Androgen Deprivation Therapy.
    Lowentritt B; Fallick M; Pruett J; Jiang T; Li E; Brown B; Dufour R
    Urol Pract; 2024 Jan; 11(1):154-161. PubMed ID: 37914225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
    Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
    BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer.
    Moussa M; Papatsoris A; Dellis A; Chakra MA; Fragkoulis C
    Expert Opin Pharmacother; 2021 Dec; 22(17):2373-2381. PubMed ID: 34187259
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.
    Muniyan S; Xi L; Datta K; Das A; Teply BA; Batra SK; Kukreja RC
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188383. PubMed ID: 32535158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.
    Merseburger AS; Bakshi G; Chen DY; Chiong E; Jabbour M; Joung JY; Lai AY; Lawrentschuk N; Le TA; Ng CF; Ng CT; Ong TA; Pang JS; Rabah DM; Ragavan N; Sase K; Suzuki H; Teo MMH; Uemura H; Woo HH
    World J Urol; 2024 Mar; 42(1):156. PubMed ID: 38483562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer.
    Lifshitz K; Ber Y; Shenhar C; Nillson J; Peer A; Rosenbaum E; Baniel J; Kedar D; Ben Zadok OI; Margel D
    J Urol; 2021 Oct; 206(4):952-959. PubMed ID: 34032505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relugolix: A Review in Advanced Prostate Cancer.
    Shirley M
    Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
    Clinton TN; Woldu SL; Raj GV
    Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS; Blank J; Graff JN
    Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
    Crawford ED; Moul JW
    Oncology (Williston Park); 2015 Jan; 29(1):55-8, 65-6. PubMed ID: 25592210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.